Skip to content

Study · Randomized controlled trial · n = 156 · 2021

6 results

Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.

Jiang J, Lin L, Chen P

Endocrine, metabolic & immune disorders drug targets1 Jan 2021Cited by 5 (Europe PMC)

PMID32875989 (opens in a new tab)DOI10.2174/1871530320999200831165116 (opens in a new tab)PepBankPUB-32875989
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, HbA1c fell less with liraglutide than with dapagliflozin; significance of the difference is not stated.

    In plain wordsIn adults with poorly controlled type 2 diabetes, HbA1c fell less with liraglutide than with dapagliflozin.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c reduction compared with dapagliflozin
    Study

    n = 156

    Comparator
    Dapagliflozin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The HbA1c level in the dapagliflozin group decreased from 8.96 ± 1.23% to 7.03 ±0.74% (P< 0.01), more than that in the liraglutide group, namely, from 8.99 ± 1.34% to 7.24 ±0.77% (P< 0.01).
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, the proportion achieving combined endpoints did not differ significantly between liraglutide and dapagliflozin.

    In plain wordsIn adults with poorly controlled type 2 diabetes, similar proportions reached the combined goals with liraglutide and dapagliflozin.

    Peptide
    Liraglutide
    Outcome
    No significant changeProportion achieving combined endpoints
    Study

    n = 156

    Comparator
    Dapagliflozin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The percentages of patients achieving combined endpoints in the two groups were of no statistical significance (P=0.204).
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with poorly controlled type 2 diabetes, added liraglutide was associated with mild adverse events.

    In plain wordsIn adults with poorly controlled type 2 diabetes, side effects with liraglutide were mild.

    Peptide
    Liraglutide
    Outcome
    Not applicableAdverse events
    Study

    n = 89

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    And there were mild adverse events in both groups.
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, added liraglutide significantly decreased body weight over 24 weeks.

    In plain wordsIn adults with poorly controlled type 2 diabetes, body weight fell significantly with liraglutide, as it also did with dapagliflozin.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 77

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The body weight of the patients in the dapagliflozin group and the liraglutide group decreased significantly (P<0.05).
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, added liraglutide decreased HbA1c from 8.99% to 7.24% over 24 weeks.

    In plain wordsIn adults with poorly controlled type 2 diabetes, HbA1c fell with added liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 77

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    HbA1c
    8.99%
    liraglutide baseline
    HbA1c
    7.24%
    liraglutide at 24 weeks

    Source sentences

    Summary
    The HbA1c level in the dapagliflozin group decreased from 8.96 ± 1.23% to 7.03 ±0.74% (P< 0.01), more than that in the liraglutide group, namely, from 8.99 ± 1.34% to 7.24 ±0.77% (P< 0.01).
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, overall treatment satisfaction was lower with liraglutide than with dapagliflozin.

    In plain wordsIn adults with poorly controlled type 2 diabetes, people were less satisfied with liraglutide than with dapagliflozin.

    Peptide
    Liraglutide
    Outcome
    DecreaseTreatment satisfaction (DTSQ)
    Study

    n: not reported in source

    Comparator
    Dapagliflozin
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    However, the overall treatment satisfaction was higher in the dapagliflozin group.
    2 context sentences
    Summary · context
    To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy.
    Summary · context
    At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.